Last reviewed 2026-04-23 · How we verify

Nefopam ampule

Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia.

Nefopam is a non-opioid analgesic that inhibits the reuptake of monoamines (norepinephrine, dopamine, and serotonin) in the central nervous system to produce analgesia. Used for Moderate acute and postoperative pain, Pain management as an adjunct or alternative to opioids.

At a glance

Mechanism of action

Nefopam works by blocking the reuptake of multiple neurotransmitters at the synaptic level, thereby increasing their availability in the central nervous system. This monoamine reuptake inhibition enhances pain modulation pathways independent of opioid receptors. It is used primarily for moderate pain relief and has stimulant properties that may counteract opioid-induced sedation.

Approved indications

• Moderate acute and postoperative pain
• Pain management as an adjunct or alternative to opioids

Common side effects

• Tachycardia
• Hypertension
• Tremor
• Sweating
• Nausea
• Dizziness

Key clinical trials

• Role of Nefopam in Rituximab Transfusion Reaction (PHASE3)
• Comparison of Two Routes of Administration of a Multimodal Analgesic Protocol in Postoperative Cesarean Section (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Nefopam ampule CI brief — competitive landscape report
• Nefopam ampule updates RSS · CI watch RSS
• Ministry Of Health / Nineveh Health Directorate portfolio CI